ARZERRA (ofatumumab) - Fatal infusion reaction reported in a patient with chronic lymphocytic leukemia - for health professional

GlaxoSmithKline Inc., in consultation with Health Canada, would like to inform you of important new safety information regarding a fatal infusion-related reaction following the use of ARZERRA™ (ofatumumab). ARZERRA™ is an anti-CD20 antibody that is authorized in Canada under a Notice of Compliance with conditions, for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. A post-marketing case of fatal infusion reaction has been reported in a patient with CLL with no known history of cardiac disease. Read more here.